ACTEMRA DIN 02483327
Status: Marketed
Holder: HOFFMANN-LA ROCHE LIMITED
Available to quote
Health Canada record
| Active ingredient(s) | TOCILIZUMAB 162 MG |
|---|
| Dosage form | Solution |
|---|
| Route | Subcutaneous |
|---|
| Schedule | SCHEDULE D; PRESCRIPTION |
|---|
| Class | Human |
|---|
| ATC | L04AC07 TOCILIZUMAB |
|---|
| Original market date | 15-Jan-2019 |
|---|
| Current status date | 15-Jan-2019 |
|---|
| Source | Health Canada DPD |
|---|
Establishment licence of the holder
Hoffmann-La Roche Limited — licence 100006, currently licensed, last inspection rating C (2024-06-25).
No Canadian shortage report is currently matched to this DIN.
Other Canadian products containing TOCILIZUMAB
| DIN | Product | Company | Form | Strength | Status |
|---|
| 02350092 | ACTEMRA | HOFFMANN-LA ROCHE LIMITED | Solution | TOCILIZUMAB 80 MG | Marketed |
| 02350106 | ACTEMRA | HOFFMANN-LA ROCHE LIMITED | Solution | TOCILIZUMAB 200 MG | Marketed |
| 02350114 | ACTEMRA | HOFFMANN-LA ROCHE LIMITED | Solution | TOCILIZUMAB 400 MG | Marketed |
| 02424770 | ACTEMRA | HOFFMANN-LA ROCHE LIMITED | Solution | TOCILIZUMAB 162 MG | Marketed |
| 02562049 | AVTOZMA | CELLTRION INC. | Solution | TOCILIZUMAB 400 MG | Marketed |
| 02562022 | AVTOZMA | CELLTRION INC. | Solution | TOCILIZUMAB 80 MG | Marketed |
| 02562030 | AVTOZMA | CELLTRION INC. | Solution | TOCILIZUMAB 200 MG | Marketed |
| 02562057 | AVTOZMA | CELLTRION INC. | Solution | TOCILIZUMAB 162 MG | Marketed |
| 02562065 | AVTOZMA | CELLTRION INC. | Solution | TOCILIZUMAB 162 MG | Marketed |
| 02552450 | TYENNE | FRESENIUS KABI CANADA LTD | Solution | TOCILIZUMAB 80 MG | Marketed |
| 02552469 | TYENNE | FRESENIUS KABI CANADA LTD | Solution | TOCILIZUMAB 200 MG | Marketed |
| 02552477 | TYENNE | FRESENIUS KABI CANADA LTD | Solution | TOCILIZUMAB 400 MG | Marketed |
| 02552485 | TYENNE | FRESENIUS KABI CANADA LTD | Solution | TOCILIZUMAB 162 MG | Marketed |
| 02552493 | TYENNE | FRESENIUS KABI CANADA LTD | Solution | TOCILIZUMAB 162 MG | Marketed |
Notices of Compliance
| NOC | Date | Submission | Reason |
|---|
| 21571 | 2018-11-28 | Supplement to a New Drug Submission (SNDS) | NEW PRESENTAITON |
Request a quote for ACTEMRA
How to read a Canadian DIN record